Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01AR082831-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | NIH |
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above.
The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether skin sodium concentration is linked to atopic dermatitis and immune profiles over time.
Participants will be asked to complete questionnaires, provide bio samples, and undergo non-contrast sodium MRI at 2-3 time points over 3-24 months.
The central hypothesis of this proposal is that excess dietary sodium (consumed primarily as salt) is concentrated in the skin as a physiologic response to poor barrier function, and that high levels of skin sodium worsen atopic dermatitis.
The study will recruit 90 individuals (30 healthy participants, 30 with mild atopic dermatitis and 30 with severe atopic dermatitis) and follow them to identify factors associated with skin sodium storage. Diet will be evaluated using food frequency questionnaires and urine biomarkers, skin sodium concentration will be measured using a non-invasive sodium MRI technique, and atopic dermatitis activity and severity will be measured using multiple patient-reported outcomes and clinician scores. Participants without atopic dermatitis will be asked to visit the research site 4 times over 3 months. Participants with atopic dermatitis will be additionally asked to complete monthly severity scores for up to 24 months total and to visit the research site an additional 2 times when their disease severity changes.
The first specific aim will evaluate the association between dietary sodium intake and skin barrier function on skin sodium concentration. The primary analysis will use regression models to determine the association between dietary sodium intake and skin sodium concentration across 2-3 time points. The association with skin barrier function will also be evaluated.
The second specific aim will evaluate the extent to which skin sodium is associated with atopic dermatitis severity and persistence. The analysis will use regression models to determine the association between skin sodium and atopic dermatitis prevalence and severity. It will also examine immune profiles associated with skin sodium.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No History of AD | Healthy controls | ||
| Mild AD | Eczema Area Severity Index (EASI): scores <7 will be considered mild AD | ||
| Severe AD | Eczema Area Severity Index (EASI): scores >21 will be considered severe |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Skin sodium concentration | Skin sodium concentration will be measured via non-contrast sodium MRI | 2 years |
| Atopc dermatitis serverity | Atopic dermatitis severity will be measured via the eczema area severity index (EASI). The score range is 0-72 and higher scores indicate more severe atopic dermatitis. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Atopic dermatitis severity and persistence | Atopic dermatitis severity and persistence will be tracked via assessments at clinic visits and via virtual monthly assessments using the Patient Oriented Eczema Measure (POEM). The POEM score ranges from 0-28 and higher scores indicate more severe atopic dematitis. | 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
(Patients on dupilumab will not be excluded if they have been on dupilumab for at least two months and still meet the criteria for severe disease.)
Not provided
Not provided
Not provided
Older adults with no history of atopic dermatitis, mild atopic dermatitis, or severe dermatitis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jie Zhu, MD | Contact | 415-502-0433 | Jie.Zhu2@ucsf.edu | |
| Katrina Abuabara, MD | Contact | 415-514-9769 | katrina.abuabara@ucsf.edu |
| Name | Affiliation | Role |
|---|---|---|
| Katrina Abuabara, M.D. | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| San Francisco VA Medical Center | Recruiting | San Francisco | California | 94115 | United States |
All IPD that underlie the results in a publication
Beginning 1 year and ending 5 years after publication of the results
Researchers interested in accessing data from the project must submit a written resource request via email to the Principal Investigator and sign a Data Use Agreement. De-identified data will be shared through a secure server.
Not provided
Not provided
| ID | Term |
|---|---|
| D004485 | Eczema |
| D003876 | Dermatitis, Atopic |
| ID | Term |
|---|---|
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood, urine, microbiome skin swabs, and saliva will be collected during each in-person visit.
After local anesthesia, one 6mm punch biopsy will be collected from patients with severe atopic dermatitis, from affected skin, for use in histopathology and/or cell culture.
| Atopic dermatitis severity |
Atopic dermatitis-associated itch will be assessed at clinic visits using the numerical rating score for itch (NRS 11). The range for the NRS is 0-10, and higher scores indicate more severe itch / worse disease. |
| 2 years |
| Atopic dermatitis severity | Atopic dermatitis severity will be measured at participant visits using the validated Investigator's Global Assessment (vIGA). The scores range from 0-4, and higher scores indicate more severe atopic dermatitis. | 2 years |
| Atopic dermatitis severity | Atopic dermatitis severity will be measured at participant visits using a Body Surface Area (BSA) estimation. The BSA ranges from 0-100 and higher scores indicate more severe disease | 2 years |
| Atopic dermatitis severity | Atopic dermatitis severity will be measured at participant visits using the Recap of Atopic Eczema (RECAP) measure of long term control. Scores range from 0-28, and higher scores indicate more severe atopic dermatitis. | 2 years |
| Atopic dermatitis severity | Atopic dermatitis severity will be measured at participant visits using the Dermatology Life Quality Index (DLQI). Scores range from 0-30, and higher scores indicate worse outcomes. | 2 years |
| UCSF Mt Zion Campus | Recruiting | San Francisco | California | 94511 | United States |
|
| D012873 |
| Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |